Archive for January, 2007

We have updated our report on psoriasis treatments in clinical trials and development and announced today that a record SEVENTY potential new treatments for psoriasis and psoriatic arthritis are in development by the biotech and pharmaceutical industries.
This is an extraordinary statistic, particularly for anyone who had psoriasis in the 1970s or 1980s, when developments were
READ THE FULL POST

We’re still reeling from Lestoil for psoriasis (don’t do it), but we’re forging ahead with this week’s latest helpful advice from American and European newspapers for how to treat the genetic, immune system disease psoriasis.
Today’s entries: seaweed and turmeric.
OK. Ice cream and tandoori chicken it is!
(Diet and psoriasis is an important topic, and
READ THE FULL POST

Happy Birthday to…us! Today is our second birthday.
And given the poor state of federal funding of psoriasis research (research on other diseases doubled over the last 10 years while research on psoriasis and psoriatic arthritis fell by 20%), we are considering a Terrible Twos Temper Tantrum in the Halls of Congress. Stay tuned
READ THE FULL POST

If you think people with psoriasis in the 21st century should be debating the topical application of Lestoil Cleaner to their skin as a treatment strategy, then you will not want to miss this syndicated health column. But if you think it is both offensive and outrageous that some desperate psoriasis patients must resort
READ THE FULL POST

The New York Times covers the business side of the biologic treatments for psoriasis. They report that the manufacturers of these treatments, and many analysts, are surprised that not more patients are using them. The article cites many possible reasons for this, including: a misperception that psoriasis is not a serious disease;
READ THE FULL POST

Abbott (makers of Humira) reported today that their Phase Two testing of their experimental psoriasis drug ABT-874 showed “outstanding” effectiveness. Nothing should make psoriasis patients feel better than seeing biotech companies in a can-you-top-this battle to help us.
ABT-874 is an anti IL-12 monoclonal antibody that would be self-injected like Enbrel, Raptiva and Humira.
READ THE FULL POST

There are about 7 million Americans with psoriasis. We vote, we pay taxes. Yet as so many of us are suffering–in pain physical, emotional, and financial–due to psoriasis and psoriatic arthritis, the federal government is preparing to spend just ONE DOLLAR for each of us this year on psoriasis research. That’s just
READ THE FULL POST

We are linking to an article from Belfast, Northern Ireland today that discusses psoriasis because it is a type of article frequently seen in newspapers across both North America and Europe, one that trivializes psoriasis and also endorses a double-standard in evaluating medical treatments. A loving wife writes in to a columnist about
READ THE FULL POST

Among the myriad potential roadblocks between a treatment being theorized and its eventually reaching patients is a drug candidate’s not fitting in with its creator’s corporate plan. In other words, companies sometimes begin developing a potential treatment but later decide to focus on other (perhaps more promising) products, or they decide that a product
READ THE FULL POST

Don’t forget our interview on HealthTalk Live this evening: 8:30 pm EST.